Caplin Point Laboratories' (NSE:CAPLIPOINT, BOM:524742) recorded a rise in its consolidated attributable profit to 1.53 billion Indian rupees in the fiscal first quarter ended June 30, against 1.24 billion rupees a year ago.
Earnings per share climbed to 20.03 rupees compared with 16.24 rupees a year earlier, the pharmaceutical company said in a filing to the Indian stock exchanges on Thursday.
Revenue from operations in fiscal Q1 also increased to 5.10 billion rupees from 4.59 billion rupees a year ago.
The company's shares were up over 3% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.